Table 2.

Selected clinical trials that incorporate mosunetuzumab in experimental therapy of B-NHL.

Drug Combination	Target Antigens	Mode of Action of the Combination Agent(s) Other Than Bispecific Antibody	Study Phase	Disease Status	Estimated Study Completion Date	ClinicalTrials.gov Identifier (Other Identifier)
Mosunetuzumab ± atezolizumab	CD20/CD3	immune check-point PD-L1 inhibitor atezolizumab	1	R/R B-NHL and CLL	October 2021	NCT02500407
Mosunetuzumab + polatuzumab vedotin compared to bendamustine + rituxumab + polatuzumab vedotin	CD20/CD3	anti-CD79B antibody-drug conjugate polatuzumab-vedotin, anti-CD20 rituximab, new cytostatic agent bendamustine	1B/2	R/R DLBCL and R/R FL	June 2022	NCT03671018
Mosunetuzumab + lenalidomide, glofitamab + lenalidomide or glofitamab + lenalidomide + obinutuzumab	CD20/CD3	immunomodulatory agent lenalidomide, glycoengeneered anti-CD20 mAb obinutuzumab	1	newly dg DLBCL, R/R DLBCL and R/R FL	August 2022	NCT04246086
Mosunetuzumab + CHOP or mosunetuzumab + polatuzumab vedotin + CHP	CD20/CD3	chemotherapy CHOP, anti-CD79B antibody drug conjugate polatuzumab-vedotin	1B/2	newly dg DLBCL, R/R B-NHL	June 2022	NCT03677141
Mosunetuzumab	CD20/CD3		1B/2	newly dg DLBCL	April 2023	NCT03677154
Mosunetuzumab or Glofitamab + GemOx	CD20/CD3	chemotherapy gemcitabine and oxaliplatin (GemOx)	1	R/R DLBCL	March 2021	NCT04313608

Abbreviations: CHOP= cyclophosphamide + doxorubicin + vincristine + prednisone; CLL= chronic lymphocytic leukemia; DLBCL= diffuse large B-cell lymphoma; FL= follicular lymphoma; PD-L1= programmed death ligand 1; R/R= relapsed/refractory; B-NHL= B cell non-Hodgkin lymphomas.